An investigational radionuclide therapy targeting prostate-specific membrane antigen (PSMA) achieved biochemical responses in 70% of patients with castration-resistant prostate cancer (CRPC), and prostate-specific antigen (PSA) reductions in all but one patient, enrolled in a small preliminary clinical trial.

Stereotactic body radiotherapy (SBRT) guided by MRI for localised prostate cancer resulted in fewer toxicities and an improvement in quality of life compared with CT guidance, according to the randomised phase III MIRAGE trial.

Excluding systematic biopsy in favour of MRI-targeted biopsy in men with elevated prostate-specific antigen (PSA) levels reduced the probability of detecting clinically insignificant cancers, but at the risk of missing some clinically significant cancers and delaying their diagnosis.

Whether it’s due to the side effects of local and systemic therapies, or the diagnosis itself, men with prostate cancer are at increased risk of mental distress and suicide. The mental health burden associated with a diagnosis and treatment is substantial, pointed out Zachary Klaassen, MD, of the Georgia Cancer Center at Augusta University.